Skip to content Provide accessibility feedback
For Providers
For Patients
Customer Stories
About Us
Contact Us
Magnifying glass Search

Rezolut adopts innovative, AI breast care solution from Volpara Health

Volpara Health – Published on October 4, 2021

Volpara ScorecardTM improves clinical decision-making with key breast density and risk insights in one view

ATLANTA, GA, OCTOBER 1, 2021 — Imaging leader Rezolut, LLC has committed to implement Volpara Health Technologies’ (ASX:VHT) innovative, AI-based breast care software at a wide range of imaging locations across the U.S. The software will provide breast cancer risk insights as part of mammography reporting. The new capability will provide the radiologist a “scorecard“ for each patient’s mammography exam that will include a precise breast density measurement and a lifetime breast cancer risk score. This information is critical for clinicians to be able to triage women to additional screening and genetic testing as needed. Both Rezolut and Volpara share core values around improving coordinated care to patients, as well to provide the most advanced technologies to help find cancers early.

Rezolut is a national, emerging platform of diagnostic medical imaging services, serving patients across the United States with 23 outpatient imaging centers and more than 50 mobile mammography units. Volpara is a global health technology software leader providing an integrated platform for personalized breast care, including automated and objective breast density assessment, mammography dose and pressure measurements and alerts.

Specifically, the Volpara ScorecardTM product combines essential metrics into a unified scorecard presentation, speeding the workflow of busy radiologists and ensuring critical information like the patient’s volumetric breast density and Volpara Density Grade are factored into any future care decisions.

“We are excited to work with Volpara and give our breast care teams the insights they need to improve clinical decision-making and provide personalized care for the benefit of our patients nation-wide,” said Rezolut CEO Dr. Jin Kim.

Volpara is committed to help Rezolut reach new heights as they personalize breast care across their broad network on centers.


About Rezolut
Rezolut is a high growth medical imaging business, committed to building an innovative, national multi-modal platform by delivering high quality service to our patients. To learn more about Rezolut, visit

About Volpara Health
Volpara provides an advanced AI software platform that works with a healthcare provider’s expertise to enable a high-quality, optimized, and personalized cancer screening experience. From the time a patient enters a clinic to the moment they obtain key results, the Volpara Breast Health Platform collects and analyzes information to better understand a patient’s breast cancer risk, while also objectively evaluating image quality and workflow-improvement opportunities. These capabilities are being extended to lung cancer screening. The Volpara Breast Health Platform is supported by numerous patents, trademarks, and regulatory registrations including FDA clearance and CE marking, and is validated by a volume of peer-reviewed publications unrivaled in the breast screening industry.